JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Prostaglandin E1 opens the ductus venosus in the newborn lamb.

There is in vitro evidence that the ductus venosus of the fetal and newborn lamb relaxes to administration of E-series prostaglandins. We performed this study to determine whether the ductus venosus of the newborn lamb could be reopened by an infusion of prostaglandin E1. Fifteen lambs between 4 and 28 h of life and six lambs between 42 and 96 h of life had portal angiograms to determine whether the ductus venosus was patent. Ten of the lambs between 4 and 28 h of age had a closed ductus venosus as did all of the lambs between 42 and 96 h of age. The lambs with a closed ductus venosus received an infusion of either prostaglandin E1 or normal saline followed by repeat portal angiography. In the 4- to 28-h-old lambs, prostaglandin E1 opened the ductus venosus in each of the five lambs who received it, while saline did not in any of the five who received it. In the 42- to 96-h-old lambs, neither prostaglandin E1 in four lambs nor saline in two lambs opened the ductus venosus. Prostaglandin E1, then, reopens the ductus venosus in the newborn lamb during the first day of life. We speculate that prostaglandin E1 may be useful in reopening the ductus venosus in certain newborn infants such as those requiring catheterization of the right atrium and those with total anomalous pulmonary venous return below the diaphragm.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app